257 related articles for article (PubMed ID: 27581246)
1. Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.
Yan X; Gu X; Zhou L; Lin H; Wu B
Clin Drug Investig; 2016 Dec; 36(12):1001-1010. PubMed ID: 27581246
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
Yan X; Gu X; Xu Z; Lin H; Wu B
Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
[TBL] [Abstract][Full Text] [Related]
3. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
5. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.
Glickman A; Brennecke A; Tayebnejad A; Matsuo K; Guntupalli SR; Sheeder J
Gynecol Oncol; 2020 Nov; 159(2):476-482. PubMed ID: 32854972
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
[TBL] [Abstract][Full Text] [Related]
14. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
Kotirum S; Chongmelaxme B; Chaiyakunapruk N
J Thromb Thrombolysis; 2017 Feb; 43(2):252-262. PubMed ID: 27704332
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Migliaccio-Walle K; Rublee D; Simon TA
Postgrad Med; 2012 Jan; 124(1):41-9. PubMed ID: 22314113
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
Folkerts K; Broughton J; Sheikh U; Mckaig S
J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
[No Abstract] [Full Text] [Related]
18. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
